Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Lizeth Evangelista
Regulatory Coordinator II
Cancer Center Division
Overview
Research
More
Collaboration
(11)
Octavio Castanos
Mutual work: 1 Grant﹒1 Proposal
Collaboration Details
Umbreen Rozell
Mutual work: 1 Grant
Collaboration Details
Jennifer Segar
Mutual work: 8 Grants
Collaboration Details
Sima Ehsani Chimeh
Mutual work: 1 Grant
Collaboration Details
Linda Garland
Mutual work: 3 Proposals
Collaboration Details
Page 1 of 3
Previous page
Next page
Grants
(8)
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
Active
·
2023
·
$0 / $830.5K
·
External
undefined (CD)
oncology,
clinical trials,
cancer treatment,
drug development,
immunotherapy
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
Active
·
2023
·
$0 / $709.8K
·
External
undefined (CD)
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
Active
·
2023
·
$0 / $391.4K
·
External
undefined (CD)
immunotherapy,
cancer,
clinical trial,
combination therapy,
solid tumors
A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients wi
Active
·
2023
·
$0 / $245.9K
·
External
undefined (CD)
immunotherapy,
oncology,
viral therapy,
clinical trial,
safety
A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants with Advanced Tumors Harbori
Active
·
2023
·
$0 / $216.2K
·
External
undefined (CD)
oncology,
pharmacokinetics,
pharmacodynamics,
clinical trial,
safety
Page 1 of 2
Previous page
Next page